Indium (111In) capromab pendetide

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).[1]

Indium (111In) capromab pendetide
Monoclonal antibody
TypeWhole antibody
TargetGlutamate carboxypeptidase II
Clinical data
Trade namesProstascint
ATC code
CAS Number
  • none
 ☒NcheckY (what is this?)  (verify)

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]


  1. ^ a b Manyak MJ (February 2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy. 8 (2): 175–81. doi:10.1586/14737140.8.2.175. PMID 18279057. S2CID 30587577.
  2. ^ WHO Drug Information
  3. ^ Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (April 1999). "A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy". Cancer Biotherapy & Radiopharmaceuticals. 14 (2): 99–111. doi:10.1089/cbr.1999.14.99. PMID 10850293.